Clinical Trial Update: Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating neoadjuvant toripalimab with stereotactic body radiotherapy for chemo-resistant triple-negative breast cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Toripalimab (Toripalimab)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: TNBC, Triple Negative Breast Cancer | Phase 2 | Status: RECRUITING